What A Whiz! Takeda Spins Off Discovery Op Axcelead Into New Fund
Takeda has spun off into a new joint investment fund selected drug discovery operations in Japan that had been shifted to the new Axcelead business last year, further honing its focus ahead of the Shire acquisition and in a move to foster a more effective early-stage ecosystem in the country.
You may also be interested in...
Takeda continues to pursue the transformation of its R&D activities, which has already led to expansion of the pipeline, but will continue with core strategies including partnering even after the huge Shire acquisition.
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.